NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Merck started 2026 on a high note. Read why MRK stock is still one of the best choices among Big Pharma players for long-term-oriented investors.

WVU Cancer Institute became the first in the world to treat ultra-rare, aggressive CD19-positive MPAL with subcutaneous ...

In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

For decades, complex infused therapies were anchored to hospitals. Higher acuity was assumed to require inpatient walls, and infusion centers were viewed primarily as transitional sites rather than ...

Cancer treatments must now go beyond the usual concerns of patients who grapple with their high costs in favor of improving quality of life, according to ...

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).